other_material
confidence high
sentiment positive
materiality 0.65
CER-1236 first-in-human data show no CRS/ICANS; platelet transfusion independence in index AML patient
CERO THERAPEUTICS HOLDINGS, INC.
- No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.
- Index patient with inv(3) AML achieved platelet transfusion independence for 72 days after multiple CER-1236 doses.
- CER-1236 successfully manufactured for all four enrolled patients; study expanded to include MDS and myelofibrosis.
- TIM-4 ligand target expressed on AML but not healthy bone marrow; no off-tumor cytotoxicity in preclinical safety assays.
item 8.01item 9.01